Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
36.60    0.10 (0.27%)
Bid:
36.50
Ask:
36.70
Spread: 0.20 (0.548%)
Market Cap: £26.87m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Interim Management Statement

4 Feb 2009 07:00

RNS Number : 7412M
Carclo plc
04 February 2009
 



For immediate release:  4 February 2009

Carclo plc

("Carclo" or "The Group")

Interim Management Statement

The Board is pleased to report that the group continues to trade in line with our expectations at the time of our Interim Statement in November 2008. The resilience of our specialist medical and optical businesses, together with strong design and development revenues in our specialist lighting business, have helped to offset the impact of weaker demand in the group's more difficult electronics and automotive markets.

In Technical Plastics, the medical businesses continue to trade well and win new contracts and LED optics volumes are growing. We have seen a reduction in volumes in this division's smaller markets, electronics and automotive components which together account for approximately 20% of group turnover. However, we are continuing to manage costs in order to maintain margins. The board has taken the decision to bring forward the planned closure of the Slough manufacturing facility and reduce future costs by redeploying the remaining production capacity to lower cost facilities within the UK. The division will retain a small technical support facility in the Slough area.

The Precision Products division delivered an excellent performance in the first half of the financial year. Our specialist lighting programmes for the supercar market have so far been largely unaffected by the turbulence in the automotive industry and design and development revenues from recent contract wins should help to underpin a very satisfactory performance for the full year. Whilst demand for antennas and cables has decreased, this has been mitigated by a good performance from our aerospace business which benefited from the acquisition of Jacottet Industrie in July 2008.

The group continues to invest in new technologies. Conductive Inkjet Technology ("CIT") is now producing volume samples of Radio-frequency identification ("RFID") components for a number of major companies in the industry and the feedback on both technical performance and achievement of cost targets is excellent. CIT's technology, which enables the design of innovative devices using printed electronics, is now being validated with customers across a range of applications in addition to RFID. These developments are very encouraging and we look forward to a significant step up in the pace of commercialisation at CIT.

Progress has also been good at Platform Diagnostics ("Platform"). This business has developed an innovative blood testing device using its patented Capillary Agglutination Technology alongside unique display and sensor systems developed by CIT. Since the half year, Carclo has increased its investment in Platform from 17.5% to 27.1% alongside our investment partner, BBI Holdings.

Since the interim results were announced, sterling has weakened against all major currencies. As the group generates a significant proportion of its profits in US dollars and Euros this has enhanced earnings. Net debt at the half year was £15.9 million. Translated at today's exchange rates this debt would be £19.5 million. To mitigate against further weakening of sterling we also converted approximately half of our US dollar debt to sterling at the end of November. We are generating cash from operations and debt remains controlled well within our total facilities of £31.9 million.

Overall, the group continues to show resilience in a challenging and volatile environment and remains well positioned in some exciting growth areas such as medical diagnostics and devices, LED optics and lighting, and printed electronics.

- ENDS -

Enquiries:

Carclo plc

01924 268040

Ian Williamson, Chief Executive

Robert Brooksbank, Finance Director

Weber Shandwick Financial

020 7067 0700

Terry Garrett or James White

Notes to editors

Carclo plc is a global supplier of technical plastic components. It is a public company whose shares are quoted on the London Stock Exchange.

70% of sales are derived from the supply of fine tolerance, injection moulded plastic components, which are used in medical, optical and electronics products. This business, Carclo Technical Plastics, operates internationally in a fast growing and dynamic market underpinned by rapid technological development.

30% of sales are derived from the supply of specialised precision products to the premium automotive and aerospace industries.

Carclo's strategy is to develop new technologies and products to drive future growth.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUUUUAPUPBGQW
Date   Source Headline
29th Apr 20264:59 pmRNSDirector Dealing – Late Notification
27th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 202610:34 amRNSHolding(s) in Company
23rd Apr 20267:00 amRNSTrading Update
24th Dec 202510:10 amRNSDirector/PDMR Shareholding
24th Dec 202510:10 amRNSDirector/PDMR Shareholding
25th Nov 20257:00 amRNSDirector/PDMR Shareholding
21st Nov 20257:00 amRNSHalf-year Financial Report
17th Nov 20257:00 amRNSNotice of Half Year Results
30th Sep 20256:20 pmRNSDirector/PDMR Shareholding
30th Sep 20256:14 pmRNSDirector/PDMR Shareholding
26th Sep 202512:30 pmRNSResult of AGM
26th Sep 20257:00 amRNSTrading Update
19th Sep 20255:58 pmRNSDirector/PDMR Shareholding
17th Sep 20257:00 amRNSChange of Auditor
11th Sep 20258:41 amRNSDirector/PDMR Shareholding
1st Sep 20257:30 amRNSRestoration - Carclo PLC
29th Aug 202511:55 amRNSNotice of AGM
29th Aug 20257:00 amRNSFull Year 2025 audited results
28th Aug 20257:00 amRNSNotice of Results and Investor Presentation
1st Aug 20257:30 amRNSSuspension - Carclo PLC
17th Jul 20254:42 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNSContract renewal strengthens revenue visibility
10th Jul 20257:00 amRNSTrading Statement & Delay in 2025 Audited Results
2nd May 202511:33 amRNSHolding(s) in Company
30th Apr 20257:00 amRNSTrading Statement
28th Apr 20255:06 pmRNSHolding(s) in Company
24th Apr 20254:02 pmRNSRefinancing Arrangements, Pension Scheme Valuation
3rd Apr 20257:00 amRNSHolding(s) in Company
6th Mar 202510:43 amRNSHolding(s) in Company
18th Feb 20255:10 pmRNSHolding(s) in Company
13th Feb 20257:00 amRNSCFO Appointment
19th Dec 20243:49 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSInterim Report and Accounts 30 September 2024
12th Nov 202411:11 amRNSNotice of Interim Results & Investor Presentation
10th Sep 20249:33 amRNSHolding(s) in Company
5th Sep 20241:30 pmRNSResult of AGM
5th Sep 20247:00 amRNSTrading Update
16th Aug 202412:32 pmRNSHolding(s) in Company
5th Aug 202412:11 pmRNSHolding(s) in Company
31st Jul 202410:00 amRNS2024 Annual Report & Accounts and Notice of AGM
30th Jul 20243:21 pmRNSHolding(s) in Company
24th Jul 20242:49 pmRNSHolding(s) in Company
24th Jul 202412:57 pmRNSHolding(s) in Company
23rd Jul 20243:48 pmRNSHolding(s) in Company
23rd Jul 20241:08 pmRNSDirector/PDMR Shareholding
18th Jul 20247:00 amRNSFinal Results
17th Jul 20241:07 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSNotice of Results
8th Jul 20248:51 amRNSBank Facilities Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.